Drew & Napier acted in the secondary listing of China Medical System Holdings Limited on the Mainboard of the SGX-ST

17 Jul 2025

Tan Khoon Jin, Seah Xin Tong, Alice Song and Kaelyn Khok, acted as solicitors to CGS International Securities Singapore Pte. Ltd., the issue manager in connection with the successful secondary listing of China Medical System Holdings Limited (“CMS”) on the Main Board of the SGX-ST. The share price of CMS surged 11.2% on its first trading day on 15 July 2025.
 
CMS is a pharmaceutical company focusing on specialty therapeutic fields, such as cardio-cerebrovascular, central nervous system, gastroenterology and ophthalmology. CMS develops global first-in-class (FIC) and best-in-class (BIC) innovative products and efficiently promotes the clinical research, development and commercialisation of such innovative products, contributing to the transformation of scientific research into clinical practices to benefit patients.
 
Singapore is the regional headquarters of CMS for its Southeast Asia and Middle East business and the group has companies in Singapore covering the entire pharmaceutical value chain of research and development, manufacturing, commercialisation and investment.
 
CMS has been listed on HKEX since 2010 and the secondary listing of CMS on the SGX-ST enables the company to further diversity its shareholder base and enhances its presence in Southeast Asia. As at the date of its listing on the SGX-ST, the market capitalisation of CMS was over S$4.5 billion.
 
You may access the Introductory Document for the secondary listing here and read more about the secondary listing in The Business Times article published on 15 July here, The Straits Times article published on 15 July here, and The Edge Singapore article published on 15 July here.